Aarey Drugs & Pharmaceuticals Ltd.

Aarey Drugs & Pharmaceuticals Ltd.

104.75
INR
-5.35
(-4.86%)
1.47EPS
62.29P/E
2.60BMarket Cap
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
2026 Y
TTM
Revenue per Share
118.78
126.94
146.32
218.95
149.09
151.68
128.33
148.77
204.2
162.64
155.47
167.21
166.77
145.93
Basic EPS, GAAP
0.63
0.65
0.77
3.03
2.64
2.8
2.48
2.79
2.72
1.49
1.84
1.42
1.4
1.47
Free Cash Flow per Basic Share
-0.8
0.49
1.83
-2.38
-8.97
-0.24
0.83
1.11
-0.71
-0.92
-1.46
1.8
-0.8
- -
Dividend per Share
- -
- -
- -
- -
- -
0.1
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
20.53
21.06
21.16
27.2
34.32
37.01
39.49
42.28
44.77
46.25
47.32
48.67
52.86
- -
Tangible Book Value per Share
20.53
21.06
21.16
27.2
34.32
37.01
39.49
42.28
44.77
46.25
47.32
48.67
52.86
- -
Basic Weighted Avg Shares
17
17
17
18
23
23
23
23
24
25
25
28
28
28
Sales/Revenue/Turnover
1,997
2,134
2,460
3,960
3,486
3,547
3,001
3,479
4,916
4,128
3,951
4,724
4,712
4,147
Operating Margin (%)
0.44
0.23
0.26
2.28
2.09
1.95
0.78
1.07
1.93
0.49
0.71
0.21
0.92
0.86
Depreciation Expense
6
11
6
6
7
10
9
9
20
16
17
19
29
32
Net Income, GAAP
11
11
13
55
62
65
58
65
66
38
47
40
40
42
Effective Tax Rate (%)
21.63
22.81
28.88
31.39
24.59
27.2
20
21.53
34.69
37.25
12.34
34.05
26.72
0.64
Profit Margin (%)
0.53
0.51
0.52
1.38
1.77
1.84
1.93
1.87
1.33
0.91
1.19
0.85
0.84
1.01
Working Capital
293
290
285
382
691
754
811
876
921
1,025
1,160
1,164
1,179
- -
LT Debt
- -
- -
1
1
1
- -
- -
- -
33
44
32
20
10
- -
Total Equity
345
354
356
492
802
866
923
989
1,136
1,174
1,328
1,385
1,504
- -
Return on Invested Capital (%)
2.68
2.51
2.65
9.68
7.33
5.19
1.69
2.5
4.9
0.84
1.51
0.39
1.69
- -
Return on Capital (%)
4.48
4.7
4.94
15.29
10.52
8.7
6.71
7.34
6.38
3.82
5.3
3.9
3.92
- -
Return on Common Equity (%)
3.09
3.11
3.63
12.92
9.55
7.84
6.48
6.81
6.17
3.26
3.74
2.97
2.75
- -

Capital Structure

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
ST Debt
- -
490
- -
LT Borrowings
- -
10
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
28
28
28
Market Capitalization
1,926
1,448
2,604

Working Capital

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
Total Current Assets
- -
2,629
- -
Cash, Cash Equivalents & STI
- -
34
- -
Accounts Receivable, Net
- -
1,297
- -
Inventories
- -
415
- -
Total Current Liabilities
- -
1,451
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
490
- -
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
16.73%
8.85%
8.62%
Free Cash Flow
-81.41%
-90.17%
-144.58%
Net Income, GAAP
31.12%
-6.63%
-1.4%
Sales/Revenue/Turnover
9.16%
8.06%
-0.26%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
1,269
1,051
1,338
1,081
4,724
2026
1,022
842
964
1,895
4,712
2027
446
- -
- -
- -
- -

Quarterly Earnings Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
0.44
0.57
0.25
0.17
1.42
2026
0.48
0.36
0.2
0.55
1.4
2027
0.36
- -
- -
- -
- -

Quarterly Dividends Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
2027
- -
- -
- -
- -
- -

Company Description

CEO
Mihir Rajesh Ghatalia
Full Time Employees
132
Sector
Health technology
Industry
Pharmaceuticals: major
Address
107, Sahakar Bhavan Mumbai MA India 400009
IPO Date
Dec 8, 1993
Business
Aarey Drugs & Pharmaceuticals Limited manufactures active pharmaceutical ingredients, pharmaceutical intermediates, and specialty chemicals; trades industrial solvents and chemicals; and provides contract manufacturing, custom synthesis, and research and development services for the pharmaceutical and chemical industries. The company produces specific APIs including Metformin, Mefenamic Acid, and Doxaphylline; intermediates such as N-Methyl Urea and Dimethyl Urea; specialty chemicals like aromatic chemicals, chemical acids, and chloralkaline products; and industrial solvents encompassing alcohols, ketones, and glycols. Its products serve pharmaceutical formulation manufacturers, merchant exporters, and various industrial sectors globally, with manufacturing facilities in Tarapur and operations primarily in India. Incorporated in 1990 and headquartered at 107, Sahakar Bhavan, 340/348 Narshi Natha Street, Masjid, Mumbai, India, the company operates as a public limited entity listed on the Bombay Stock Exchange under the ticker AAREYDRUGS.NS. In recent developments, Aarey Drugs & Pharmaceuticals approves a preferential issue of shares or warrants at its board meeting on December 4, 2024, to raise funds; allots convertible warrants pursuant to a preferential issue; announces plans to issue 5 million warrants; and receives funding as reported in early 2025. The company also appoints a new Company Secretary and Compliance Officer in March 2025, changes its Registrar and Transfer Agent, and reappoints a director amid ongoing strategic funding efforts. These initiatives support business expansion and capital strengthening within the last year.